Literature DB >> 7988201

A comparison of commercial jet nebulizers.

D T Loffert1, D Ikle, H S Nelson.   

Abstract

Seventeen commercially available jet nebulizers from 15 commercial sources were studied (Acorn-I, Acorn-II, AquaTower, AVA-NEB, Cirrhus, Dart, DeVilbiss 646, Downdraft, Fan Jet, MB-5, Misty Neb, PARI LC JET, PARI-JET, Salter 8900, Sidestream, Updraft-II, Whisper Jet). All nebulizers were filled with 2 ml of saline solution plus 0.5 ml of albuterol and powered with the same source (DeVilbiss PulmoAide). We compared total output (TO), time for total output (TTO), and percent output in respirable range (PORR). The TO was obtained by weighing before nebulization and at the point of eight-fold decline in output. The TTO was calculated from initiation of nebulization to the point of eightfold decline in output. The PORR was measured by a laser particle analyzer in continuous nebulization to the same point of abrupt drop in output. The TO varied from 0.98 To 1.86 ml (p < 0.0001) with the Acorn-I, Acorn-II, Updraft-II, and Sidestream, significantly greater than the others (p < 0.05). The TTO varied from 2.28 to 20.95 min (p < 0.0001). The AquaTower, PARI LC JET and PARI-JET, DeVilbiss, and Dart were significantly shorter than the others (p < 0.05). The PORR varied from 21.89 to 71.95 percent (p < 0.0001). The Sidestream was significantly greater than all others (p < 0.05). The PARI LC JET and PARI-JET were, in turn, significantly greater than the remaining models (p < 0.05). To combine these characteristics, we calculated respirable particle delivery rate (RPDR) by dividing TO by TTO and multiplying by PORR. The RPDR varied from 0.03 ml/min to 0.26 ml/min (p < 0.0001). The PARI LC JET (0.24 ml/min) and the PARI-JET (0.26 mg/min) had a RPDR that was significantly greater than the other models except the AquaTower, which, however, had a markedly variable performance. The Sidestream (0.19 mg/ml) did not differ significantly from the above group, nor from the DeVilbiss and Downdraft. All other models had significantly lower outputs (p < 0.05). We conclude that the output characteristics of commercial nebulizers vary greatly and will impact on the time required for treatment as well as the total amount of drug delivered to the lungs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988201     DOI: 10.1378/chest.106.6.1788

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

Review 1.  Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

2.  Inhalation devices.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

Review 3.  Non-impactor-based methods for sizing of aerosols emitted from orally inhaled and nasal drug products (OINDPs).

Authors:  Jolyon Mitchell; Richard Bauer; Svetlana Lyapustina; Terrence Tougas; Volker Glaab
Journal:  AAPS PharmSciTech       Date:  2011-07-22       Impact factor: 3.246

4.  Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer.

Authors:  B J Lipworth; D J Clark
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

Review 5.  A risk-benefit assessment of corticosteroids in the management of croup.

Authors:  R W Yates; I J Doull
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.606

6.  Selecting and using nebuliser equipment.

Authors:  A H Kendrick; E C Smith; R S Wilson
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

Review 7.  Antiasthmatic drug delivery in children.

Authors:  Elizabeth Biggart; Andrew Bush
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 8.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 9.  Metered dose inhalers versus nebulizers for aerosol bronchodilator delivery for adult patients receiving mechanical ventilation in critical care units.

Authors:  Agi Holland; Fiona Smith; Kay Penny; Gill McCrossan; Linda Veitch; Caroline Nicholson
Journal:  Cochrane Database Syst Rev       Date:  2013-06-06

10.  An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation.

Authors:  Xuemei Zhang; Qing Liu; Junhua Hu; Ling Xu; Wen Tan
Journal:  Acta Pharm Sin B       Date:  2014-01-18       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.